A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma

OVARTIS FARMA S.p.A.0 个研究点目标入组 28 人开始时间: 2013年6月25日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•- Age >18 years.
•- Diagnosis of locally advanced or metastatic melanoma along with written documentation of BRAF V600 mutation.
•- ECOG performance status of 0 – 2.
•- Patients enrolled into Phase Ib must have evidence of evaluable and/or measurable disease as determined by RECIST v1.1.
•- Patients enrolled into Phase II (BRAFi naïve and resistant) must have evidence of measurable
•disease as determined by RECIST v1.1.
•- Archival tumor tissue must be obtained for patients enrolled in Phase Ib and Phase II arm 1a/b- BRAFi naïve patients. If an archival tumor tissue is
•not available, a fresh tumor sample is acceptable.
•- For patients enrolled in the phase II arm 2, patients must agree to undergo a fresh tumor biopsy unless one was collected prior to study entry
•but at the time of disease relapse from the most recent BRAFi treatment.
•Other, protocol related inclusion criteria may apply.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•- Symptomatic brain metastases.
•- Symptomatic or untreated leptomeningeal disease.
•- Patients with inadequate laboratory values during screening.
•- In the phase II BRAFi naïve arms (1a/b), prior exposure to CDK4/6 inhibitor (e.g., PD 0332991)
•- Impaired cardiac function or clinically significant cardiac diseases.
•- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LEE011 or LGX818.
•- Patients with concurrent severe and/or uncontrolled concurrent medical conditions.
•- Previous or concurrent malignancy.
•- Major surgery < 2 weeks before starting study treatment
•- Known diagnosis of human immunodeficiency virus (HIV) or hepatitis

发起方

OVARTIS FARMA S.p.A.